Compounders Research Compare

enGene Holdings Inc.(ENGN)

Biotechnology · Montreal, QC

$1.83-0.05 (-2.41%)

Delayed quote: Oct 6, 2026, 12:30 PM EDT

About enGene Holdings Inc.

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

Montreal, QC

82 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ronald H. W. Cooper

View full financials

enGene Holdings (ENGN) EV/EBITDA: History & Chart | TGMCharts

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T16:32:07.454Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:32:07.454Z.

Quote observation: 2026-10-06T16:30:06.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 122,255,763
Total debt · period ending 2026-07-31: 33,271,000
Cash · period ending 2026-07-31: 41,025,000
TTM operating EBITDA · period ending 2026-07-31: -3,966,000

FMP input reference: fb57f85ed843ad7a76bd5b785e55fde6d0feef1b4d3f081c49812093a2178ef2

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ENGN EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

ENGN Competitors' EV/EBITDA Ratio

enGene Holdings Inc.

Current

Market Cap

$122.26M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TuHURA Biosciences, Inc.

Market Cap

$121.95M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cibus, Inc.

Market Cap

$122.13M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Seer, Inc.

Market Cap

$121.23M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NRx Pharmaceuticals, Inc.

Market Cap

$125.34M

EV/EBITDA Ratio

N/A

TTM Avg

3271.29x

3Y Avg

2827.81x

5Y Avg

2827.81x

Entera Bio Ltd.

Market Cap

$126.43M

EV/EBITDA Ratio

N/A

TTM Avg

3.93x

3Y Avg

3.93x

5Y Avg

3.93x

LENZ Therapeutics, Inc.

Market Cap

$118.05M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Caribou Biosciences, Inc.

Market Cap

$117.53M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Coya Therapeutics, Inc.

Market Cap

$116.82M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Genelux Corporation

Market Cap

$115.69M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
enGene Holdings Inc. (ENGN)	$122.26M	N/A	N/A	N/A	N/A
TuHURA Biosciences, Inc. (HURA)vs ›	$121.95M	N/A	N/A	N/A	N/A
Cibus, Inc. (CBUS)vs ›	$122.13M	N/A	N/A	N/A	N/A
Seer, Inc. (SEER)vs ›	$121.23M	N/A	N/A	N/A	N/A
NRx Pharmaceuticals, Inc. (NRXP)vs ›	$125.34M	N/A	3271.29x	2827.81x	2827.81x
Entera Bio Ltd. (ENTX)vs ›	$126.43M	N/A	3.93x	3.93x	3.93x
LENZ Therapeutics, Inc. (LENZ)vs ›	$118.05M	N/A	N/A	N/A	N/A
Caribou Biosciences, Inc. (CRBU)vs ›	$117.53M	N/A	N/A	N/A	N/A
Coya Therapeutics, Inc. (COYA)vs ›	$116.82M	N/A	N/A	N/A	N/A
Genelux Corporation (GNLX)vs ›	$115.69M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics